drughunter.com
8 minute read
Oct. 7, 2024

Patent Highlights: pan-KRAS Inhibitors, Tumor Cell-Activated KARS (not KRAS) Inhibitors, MK2 Degraders, IL-17A Inhibitors, and More!

Author:  
Reviewer:  
Editor:  
Loading...

twitterlinkedinemail

Other articles you may be interested in

Drug Hunter Annotated Patent Database Search

As part of our series of monthly patent roundup articles, which bring you highlights of the most relevant drug discovery IP disclosures, by member request we have collated recent selections into a single searchable table. This tool allows you to see longer-term industry trends in therapeutic areas and target selection to inspire ideas for your pipeline.

September 2024 Annotated Searchable Patent Table

Staying on top of the latest IP disclosures in drug discovery is no small feat, so we’ve made it easier for you! Our team sifted through thousands of recently published patents to compile a curated list of about 200 significant patent documents in the drug discovery space from September 2024. Each entry is accompanied by detailed annotations to help you quickly grasp the essentials.

Patent Highlight: Tau-Targeting Heterobifunctional Degraders from Arvinas for Neurological Diseases

This article highlights a patent application from Arvinas that discloses the biological activity of compounds that act as tau-targeting heterobifunctional degraders, providing a summary of key data for selected molecules disclosed in the patent application.

Monte Rosa's Molecular Glue Degraders of VAV1 Exploit a Non-Canonical Degron

This article highlights a patent application from Monte Rosa Therapeutics that discloses the biological activity of compounds that act as VAV1 molecular glue degraders, providing a summary of key data for selected molecules disclosed in the patent application.

July 2024 Annotated Searchable Patent Table

To streamline your review of the patent literature, we've distilled thousands of new documents into a searchable table featuring over 200 selected patents focused on key areas in drug discovery, all published in July 2024. Each patent includes commentary for easier navigation and understanding.